Explore All 87 IPO Communications Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | September 9, 1999 |
| Target | Charter Communications |
| Sector | Communications |
| Sellers(s) | Vulcan Capital |
| Deal Type | IPO |
FILTER BY
| Category | Family Office |
|---|---|
| Founded | 1986 |
| Size | Mega |
| Type | Sector Agnostic |
Vulcan Capital is the private investment group of Vulcan Inc., the organization founded by Paul G. Allen to manage his personal and professional endeavors. Vulcan Capital looks to invest at all company stages and will consider opportunities across an array of industries. Sectors of interest include business services, consumer products, distribution and logistics, energy and natural resources, financial services and insurance, healthcare, manufacturing, media, technology, and telecom. The Firm's target investment size is $10 to $100 million. In addition to direct investing, Vulcan Capital also makes fund investments as well as invests in public securities. Vulcan Inc. was formed in 1986 and has offices in Seattle, Washington and Palo Alto, California.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 30 |
| Sector: Communications | 1 of 1 |
| Type: IPO | 1 of 9 |
| State: Connecticut | 1 of 1 |
| Country: United States | 1 of 28 |
| Year: 1999 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 1998-01-01 |
Charter Communications
Stamford, Connecticut, United States Charter Communications is a broadband communications company. Charter provides a full range of advanced broadband services, including advanced Charter Spectrum TV video entertainment programming, Charter Spectrum Internet® access, and Charter Spectrum Voice. Charter Communications was incorporated in 1993 and is based in Stamford, Connecticut. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2001-09-19 |
PTC Therapeutics
South Plainfield, New Jersey, United States PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. PTC Therapeutics was founded in 1998 and is based in South Plainfield, New Jersey. |
Buy | - |
